Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SH) Latest Company News

Oct 30, 2026, 07:46 UTC
Huiyu Pharmaceutical reported third-quarter 2026 revenue of 314 million yuan, up 8.74% year over year, and first-nine-month revenue of 866 million yuan, up 16.71%.
Source:
- finance.sina.cn
Oct 26, 2026, 10:54 UTC
Italy’s medicines agency and Portugal’s medicines regulator approved marketing of HEC’s decitabine for injection (50 mg) and zoledronic acid injection (4 mg/100 ml), as announced by HEC Pharmaceutical’s subsidiary Seacross (Europe) Pharma Ltd.
Source:
- finance.sina.cn
Sep 17, 2026, 09:16 UTC
Huiyu Pharmaceutical shareholder Huang Qianyi plans to passively reduce up to 2.46% of the company's shares (no more than 15.3923 million shares) via centralized bidding and block trades between October 19, 2026 and January 16, 2027 due to judicial enforcement.
Source:
- finance.sina.cn
- xg.stock.cnfol.com
Sep 14, 2026, 15:28 UTC
Huiyu Pharmaceutical said it will continue to expand the scope of AI tool applications based on actual R&D scenarios.
Source:
- yicai.com
Aug 19, 2026, 09:07 UTC
Huiyu Pharmaceutical's wholly-owned subsidiary Huiyu Haiyue received approval from China's National Medical Products Administration to conduct clinical trials for its investigational drug HY07121 (subcutaneous injection) for treating advanced solid tumors.
Source:
- finance.sina.cn
- wap.eastmoney.com
Aug 10, 2026, 09:04 UTC
Huiyu Pharmaceutical's subsidiary Seacross (Europe) Pharma Ltd. received marketing approvals from German, Dutch, and Spanish regulators for its products parecoxib sodium for injection and zoledronic acid injection.
Source:
- finance.sina.cn

688553.SH

Huiyu Pharmaceutical reported third-quarter 2026 revenue of 314 million yuan, up 8.74% year over year, and first-nine-month revenue of 866 million yuan, up 16.71%.

Italy’s medicines agency and Portugal’s medicines regulator approved marketing of HEC’s decitabine for injection (50 mg) and zoledronic acid injection (4 mg/100 ml), as announced by HEC Pharmaceutical’s subsidiary Seacross (Europe) Pharma Ltd.

Huiyu Pharmaceutical shareholder Huang Qianyi plans to passively reduce up to 2.46% of the company's shares (no more than 15.3923 million shares) via centralized bidding and block trades between October 19, 2026 and January 16, 2027 due to judicial enforcement.

Huiyu Pharmaceutical said it will continue to expand the scope of AI tool applications based on actual R&D scenarios.

Huiyu Pharmaceutical's wholly-owned subsidiary Huiyu Haiyue received approval from China's National Medical Products Administration to conduct clinical trials for its investigational drug HY07121 (subcutaneous injection) for treating advanced solid tumors.

Huiyu Pharmaceutical's subsidiary Seacross (Europe) Pharma Ltd. received marketing approvals from German, Dutch, and Spanish regulators for its products parecoxib sodium for injection and zoledronic acid injection.